This article is certainly republished with kind authorization from our close friends at the The Kaiser Family Foundation. You can view the complete Kaiser Daily Health Plan Statement, search the archives, or join email delivery of in-depth coverage of wellness policy developments, discussions and debates. The Kaiser Daily Wellness Policy Report is published for Kaisernetwork.org, a free support of The Henry J. Kaiser Family Foundation. Copyright 2006 Advisory Panel Kaiser and Company Family members Foundation.In the U.S. Trial, among survivors at the time of data cutoff, the median follow-up from the first vemurafenib dose was 11.7 months . At 12 months, the rate of progression-free survival was 73 percent and the price of general survival was 91 percent . Disease progression occurred in 7 of 24 patients , including 3 individuals who had got a total response and 4 who had experienced a partial response . At 12 months after response, the cumulative incidence of relapse was 27 percent .